FY2025 EPS Estimates for Metsera Cut by Cantor Fitzgerald

Metsera, Inc. (NASDAQ:MTSR) – Analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Metsera in a note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will earn ($3.58) per share for the year, down from their previous estimate of ($3.38). Cantor Fitzgerald has a “Overweight” rating on the stock.

A number of other research firms have also issued reports on MTSR. Evercore ISI initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating for the company. Bank of America began coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price for the company. Finally, Guggenheim started coverage on Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target on the stock.

Metsera Stock Performance

Shares of NASDAQ MTSR opened at $24.51 on Monday. Metsera has a 12-month low of $23.08 and a 12-month high of $32.81.

Metsera (NASDAQ:MTSR) last issued its earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.